Paul W Sperduto1, Ryan Shanley2, Xianghua Luo3, David Andrews4, Maria Werner-Wasik5, Richard Valicenti6, Jean-Paul Bahary7, Luis Souhami8, Minhee Won9, Minesh Mehta10. 1. Metro-Minnesota CCOP and Minneapolis Radiation Oncology, Minneapolis, Minnesota. Electronic address: psperduto@mropa.com. 2. Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota. 3. Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota; Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, Minnesota. 4. Thomas Jefferson University, Department of NeuroOncology, Philadelphia, Pennsylvania. 5. Thomas Jefferson University, Department of Radiation Oncology, Philadelphia, Pennsylvania. 6. UC Davis Medical Center, Department of Radiation Oncology, Sacramento, California. 7. CHUM Hospital Notre Dame, Quebec, Canada. 8. McGill University, Montreal, Quebec, Canada. 9. NRG Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania. 10. University of Maryland Medical System, Baltimore, Maryland.
Abstract
PURPOSE:Radiation Therapy Oncology Group (RTOG) 9508 showed a survival advantage for patients with 1 but not 2 or 3 brain metastasis (BM) treated withwhole-brain radiation therapy (WBRT) and stereotactic radiosurgery (SRS) versus WBRT alone. An improved prognostic index, the graded prognostic assessment (GPA) has been developed. Our hypothesis was that if the data from RTOG 9508 were poststratified by the GPA, the conclusions may vary. METHODS AND MATERIALS: In this analysis, 252 of the 331 patients were evaluable by GPA. Of those, 211 had lung cancer. Breast cancer patients were excluded because the components of the breast GPA are not in the RTOG database. Multiple Cox regression was used to compare survival between treatment groups, adjusting for GPA. Treatment comparisons within subgroups were performed with the log-rank test. A free online tool (brainmetgpa.com) simplified GPA use. RESULTS: The fundamental conclusions of the primary analysis were confirmed in that there was no survival benefit overall for patients with 1 to 3 metastases; however, there was a benefit for the subset of patients with GPA 3.5 to 4.0 (median survival time [MST] for WBRT + SRS vs WBRT alone was 21.0 versus 10.3 months, P=.05) regardless of the number of metastases. Among patients with GPA 3.5 to 4.0 treated with WBRT and SRS, the MST for patients with 1 versus 2 to 3 metastases was 21 and 14.1 months, respectively. CONCLUSIONS: This secondary analysis of predominantly lung cancer patients, consistent with the original analysis, shows no survival advantage for the group overall when treated with WBRT and SRS; however, in patients with high GPA (3.5-4), there is a survival advantage regardless of whether they have 1, 2, or 3 BM. This benefit did not extend to patients with lower GPA. Prospective validation of this survival benefit for patients with multiple BM and high GPA when treated with WBRT and SRS is warranted.
RCT Entities:
PURPOSE: Radiation Therapy Oncology Group (RTOG) 9508 showed a survival advantage for patients with 1 but not 2 or 3 brain metastasis (BM) treated with whole-brain radiation therapy (WBRT) and stereotactic radiosurgery (SRS) versus WBRT alone. An improved prognostic index, the graded prognostic assessment (GPA) has been developed. Our hypothesis was that if the data from RTOG 9508 were poststratified by the GPA, the conclusions may vary. METHODS AND MATERIALS: In this analysis, 252 of the 331 patients were evaluable by GPA. Of those, 211 had lung cancer. Breast cancerpatients were excluded because the components of the breast GPA are not in the RTOG database. Multiple Cox regression was used to compare survival between treatment groups, adjusting for GPA. Treatment comparisons within subgroups were performed with the log-rank test. A free online tool (brainmetgpa.com) simplified GPA use. RESULTS: The fundamental conclusions of the primary analysis were confirmed in that there was no survival benefit overall for patients with 1 to 3 metastases; however, there was a benefit for the subset of patients with GPA 3.5 to 4.0 (median survival time [MST] for WBRT + SRS vs WBRT alone was 21.0 versus 10.3 months, P=.05) regardless of the number of metastases. Among patients with GPA 3.5 to 4.0 treated with WBRT and SRS, the MST for patients with 1 versus 2 to 3 metastases was 21 and 14.1 months, respectively. CONCLUSIONS: This secondary analysis of predominantly lung cancerpatients, consistent with the original analysis, shows no survival advantage for the group overall when treated with WBRT and SRS; however, in patients with high GPA (3.5-4), there is a survival advantage regardless of whether they have 1, 2, or 3 BM. This benefit did not extend to patients with lower GPA. Prospective validation of this survival benefit for patients with multiple BM and high GPA when treated with WBRT and SRS is warranted.
Authors: Paul W Sperduto; Norbert Kased; David Roberge; Zhiyuan Xu; Ryan Shanley; Xianghua Luo; Penny K Sneed; Samuel T Chao; Robert J Weil; John Suh; Amit Bhatt; Ashley W Jensen; Paul D Brown; Helen A Shih; John Kirkpatrick; Laurie E Gaspar; John B Fiveash; Veronica Chiang; Jonathan P S Knisely; Christina Maria Sperduto; Nancy Lin; Minesh Mehta Journal: Int J Radiat Oncol Biol Phys Date: 2011-04-15 Impact factor: 7.038
Authors: Paul W Sperduto; Norbert Kased; David Roberge; Zhiyuan Xu; Ryan Shanley; Xianghua Luo; Penny K Sneed; Samuel T Chao; Robert J Weil; John Suh; Amit Bhatt; Ashley W Jensen; Paul D Brown; Helen A Shih; John Kirkpatrick; Laurie E Gaspar; John B Fiveash; Veronica Chiang; Jonathan P S Knisely; Christina Maria Sperduto; Nancy Lin; Minesh Mehta Journal: J Clin Oncol Date: 2011-12-27 Impact factor: 44.544
Authors: Vinai Gondi; Wolfgang A Tome; James Marsh; Aaron Struck; Amol Ghia; Julius V Turian; Søren M Bentzen; John S Kuo; Deepak Khuntia; Minesh P Mehta Journal: Radiother Oncol Date: 2010-04-12 Impact factor: 6.280
Authors: Susan Guo; Chandana A Reddy; Samuel T Chao; John H Suh; Gene H Barnett; Michael A Vogelbaum; Gregory M Videtic Journal: Lung Cancer Date: 2012-04-27 Impact factor: 5.705
Authors: Anna Likhacheva; Chelsea C Pinnix; Neil Parikh; Pamela K Allen; Nandita Guha-Thakurta; Mary McAleer; Erik P Sulman; Anita Mahajan; Almon Shiu; Dershan Luo; Max Chiu; Paul D Brown; Sujit S Prabhu; Eric L Chang Journal: J Neurosurg Date: 2012-12 Impact factor: 5.115
Authors: Chirag G Patil; Katie Pricola; J Manuel Sarmiento; Sachin K Garg; Andrew Bryant; Keith L Black Journal: Cochrane Database Syst Rev Date: 2017-09-25
Authors: Yufei Liu; Brian M Alexander; Yu-Hui Chen; Margaret C Horvath; Ayal A Aizer; Elizabeth B Claus; Ian F Dunn; Alexandra J Golby; Mark D Johnson; Scott Friesen; Edward G Mannarino; Matthew Wagar; Fred L Hacker; Nils D Arvold Journal: J Neurooncol Date: 2015-06-25 Impact factor: 4.130
Authors: Paul W Sperduto; T Jonathan Yang; Kathryn Beal; Hubert Pan; Paul D Brown; Ananta Bangdiwala; Ryan Shanley; Norman Yeh; Laurie E Gaspar; Steve Braunstein; Penny Sneed; John Boyle; John P Kirkpatrick; Kimberley S Mak; Helen A Shih; Alex Engelman; David Roberge; Nils D Arvold; Brian Alexander; Mark M Awad; Joseph Contessa; Veronica Chiang; John Hardie; Daniel Ma; Emil Lou; William Sperduto; Minesh P Mehta Journal: Int J Radiat Oncol Biol Phys Date: 2016-06-14 Impact factor: 7.038
Authors: Michela Buglione; Sara Pedretti; Stefano Gipponi; Luciano Buttolo; Paolo Panciani; Pietro Luigi Poliani; Roberto Liserre; Paolo Borghetti; Ludovica Pegurri; Loredana Costa; Luca Triggiani; Nadia Pasinetti; Paolo Ghirardelli; Sara Pandini; Alessandro Padovani; Stefano Maria Magrini Journal: Radiol Med Date: 2015-04-28 Impact factor: 3.469
Authors: Paul W Sperduto; Shane Mesko; Jing Li; Daniel Cagney; Ayal Aizer; Nancy U Lin; Eric Nesbit; Tim J Kruser; Jason Chan; Steve Braunstein; Jessica Lee; John P Kirkpatrick; Will Breen; Paul D Brown; Diana Shi; Helen A Shih; Hany Soliman; Arjun Sahgal; Ryan Shanley; William A Sperduto; Emil Lou; Ashlyn Everett; Drexell H Boggs; Laura Masucci; David Roberge; Jill Remick; Kristin Plichta; John M Buatti; Supriya Jain; Laurie E Gaspar; Cheng-Chia Wu; Tony J C Wang; John Bryant; Michael Chuong; Yi An; Veronica Chiang; Toshimichi Nakano; Hidefumi Aoyama; Minesh P Mehta Journal: J Clin Oncol Date: 2020-09-15 Impact factor: 44.544